The efficacy and safety of tranexamic acid on perioperative blood loss in patients with fracture: a prospective, randomized, controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048217

Enrollment

Unknown

Registered

2021-07-05

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip and knee jiont disease

Interventions

Control group:normal saline

Experimental group:tranexamic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Fresh femoral shaft fractures, intertrochanteric fractures, subtrochanteric fractures, pelvic and acetabular fractures, distal femoral fractures, tibial plateau fractures, pilon fractures, ankle fractures, calcaneus fractures.

Exclusion criteria

Exclusion criteria: 1. Active bleeding (such as active gastrointestinal bleeding, cerebral hemorrhage, etc.); 2. Combined with venous thromboembolism (such as deep vein thrombosis, pulmonary embolism, etc.); 3. Coagulation disorders; 4. Combined with severe neuromuscular disease; 5. Allergy to tranexamic acid.

Design outcomes

Primary

Measure	Time frame
The total blood loss;Preoperative blood loss;Hidden blood loss;	—

Secondary

Measure	Time frame
D-dimer;Fibrin degradation products;IL-6;IL-8;	—

Countries

China

Contacts

Public ContactHuang Wei

The First Affiliated Hospital of Chongqing Medical University

huangw511@163.com+86 17880267665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026